Chihiro Sumida
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Chihiro Sumida has a total of 29 co-authors. Here are the top co-authors by number of shared publications:
- Akiko Sasaki
Gastroenterology Medicine Center Shonan Kamakura General Hospital Kamakura Kanagawa Japan
6 shared publications - Chikamasa Ichita
Department of Health Data Science, Graduate School of Data Science, Yokohama City University, Yokohama, Japan
6 shared publications - Makomo Makazu
Gastroenterology Medicine Center, Shonan Kamakura General Hospital, Kamakura, Japan
4 shared publications - Takashi Nishino
Department of Gastroenterology, Medicine Center, Shonan Kamakura General Hospital, Kamakura City, Kanagawa, Japan
4 shared publications - Haruki Uojima
Department of Gastroenterology Kitasato University School of Medicine Sagamihara Kanagawa Japan
3 shared publications - Jun Kubota
Gastroenterology Medicine Center, Shonan Kamakura General Hospital, 1370-1 Okamoto, Kamakura, Kanagawa, 247-8533, Japan.
3 shared publications
Latest Publications
- Open Access
Cronkhite–Canada Syndrome With Multiple Mesenteric Lymphadenopathy: A Case Report
Cronkhite–Canada syndrome (CCS) is a rare nonhereditary disorder characterized by multiple gastrointestinal polyps and ectodermal changes. The mortality rate can reach up to 50% in patients with delayed diagnosis or inadequate treatment. A 78‐year‐old Japanese woman presented with diarrhea as the primary complaint. Her clinical presentation included diarrhea, dysgeusia, anorexia, and weight loss. Physical examination revealed alopecia, nail atrophy, and hyperpigmentation. Abdominal computed tomography (CT) revealed multiple enlarged mesenteric lymph nodes, whereas endoscopic examination showed numerous hyperplastic polyps extending from the stomach to the colon. Following the diagnosis of CCS, the patient was treated with prednisolone (30 mg/day). Abdominal CT imaging one month later showed a reduction in the mesenteric lymph node size. Although it is uncommon, mesenteric lymphadenopathy can appear in CCS and may regress with corticosteroid therapy.
Open AccessCronkhite–Canada Syndrome With Multiple Mesenteric Lymphadenopathy: A Case Report
Cronkhite–Canada syndrome (CCS) is a rare nonhereditary disorder characterized by multiple gastrointestinal polyps and ectodermal changes. The mortality rate can reach up to 50% in patients with delayed diagnosis or inadequate treatment. A 78‐year‐old Japanese woman presented with diarrhea as the primary complaint. Her clinical presentation included diarrhea, dysgeusia, anorexia, and weight loss. Physical examination revealed alopecia, nail atrophy, and hyperpigmentation. Abdominal computed tomography (CT) revealed multiple enlarged mesenteric lymph nodes, whereas endoscopic examination showed numerous hyperplastic polyps extending from the stomach to the colon. Following the diagnosis of CCS, the patient was treated with prednisolone (30 mg/day). Abdominal CT imaging one month later showed a reduction in the mesenteric lymph node size. Although it is uncommon, mesenteric lymphadenopathy can appear in CCS and may regress with corticosteroid therapy.
- Open Access
- 15 November 2024
- Published by Wolters Kluwer Health in Medicine
- Vol. 103 (46) , e40492
Characteristics of gastric cancers developed more than 10 years after eradication of Helicobacter pylori
Helicobacter pylori (H pylori) eradication is expected to effectively prevent gastric cancer (GC). However, GC cases may occur even longer than 10 years after H pylori eradication (L10AE). Moreover, the associated factors and characteristics are unknown. In this retrospective, single-center study conducted between 2017 and 2022, patients with GC diagnosed after H pylori eradication were enrolled and categorized into groups according to whether they were shorter than 10 years after H pylori eradication (S10AE) or L10AE. Patients were also categorized according to the depth of cancer invasion. Clinical data, pathological data, and risk factors were analyzed using logistic regression. Clinicopathological characteristics of GC diagnosed at L10AE and those invading the submucosal tissue or deeper (SMD) were investigated. In total, 202 cases of GC occurring after H pylori eradication were identified. Comparison of 158 S10AE and 44 L10AE GC cases revealed a significantly longer surveillance interval (SI) in L10AE cases (median: 2.0 vs 1.0 years, P = .01). Comparison of 150 intramucosal and 52 SMD GC cases revealed that L10AE GC cases were significantly more frequent amongst the SMD cases (18.0% vs 32.7%, P = .03). Pathologically, undifferentiated and mixed types were significantly more frequent in GC cases with SMD invasion (P < .001). Multivariate analysis revealed that L10AE was significantly related to GC cases with SMD invasion (odds ratio, 2.45; 95% confidence interval, 1.15–5.11; P = .019). SI was significantly longer in GC that developed at L10AE than at S10AE. In addition, GC with SMD invasion was more frequently detected in L10AE than in S10AE. Our data indicated that SI should not be groundlessly extended in patients at L10AE.
- 15 November 2024
- Published by Wolters Kluwer Health in Medicine
- Vol. 103 (46) , e40492
Open AccessCharacteristics of gastric cancers developed more than 10 years after eradication of Helicobacter pylori
Helicobacter pylori (H pylori) eradication is expected to effectively prevent gastric cancer (GC). However, GC cases may occur even longer than 10 years after H pylori eradication (L10AE). Moreover, the associated factors and characteristics are unknown. In this retrospective, single-center study conducted between 2017 and 2022, patients with GC diagnosed after H pylori eradication were enrolled and categorized into groups according to whether they were shorter than 10 years after H pylori eradication (S10AE) or L10AE. Patients were also categorized according to the depth of cancer invasion. Clinical data, pathological data, and risk factors were analyzed using logistic regression. Clinicopathological characteristics of GC diagnosed at L10AE and those invading the submucosal tissue or deeper (SMD) were investigated. In total, 202 cases of GC occurring after H pylori eradication were identified. Comparison of 158 S10AE and 44 L10AE GC cases revealed a significantly longer surveillance interval (SI) in L10AE cases (median: 2.0 vs 1.0 years, P = .01). Comparison of 150 intramucosal and 52 SMD GC cases revealed that L10AE GC cases were significantly more frequent amongst the SMD cases (18.0% vs 32.7%, P = .03). Pathologically, undifferentiated and mixed types were significantly more frequent in GC cases with SMD invasion (P < .001). Multivariate analysis revealed that L10AE was significantly related to GC cases with SMD invasion (odds ratio, 2.45; 95% confidence interval, 1.15–5.11; P = .019). SI was significantly longer in GC that developed at L10AE than at S10AE. In addition, GC with SMD invasion was more frequently detected in L10AE than in S10AE. Our data indicated that SI should not be groundlessly extended in patients at L10AE.
- Open Access
- 17 November 2023
- Published by Wolters Kluwer Health in Medicine
- Vol. 102 (46) , e34951
Exploration of predictors associated with bleeding in computed tomography-guided core needle splenic biopsy: A retrospective study
Splenic diseases may be caused by infections and can be either malignant, such as lymphoma and lung cancer, or benign, such as hemangioma. In some cases, diagnostic uncertainty of imaging persists, and image-guided splenic needle biopsy is a useful diagnostic tool to avoid the disadvantages of incorrect diagnosis, including performing unnecessary splenectomy or not giving the necessary treatment. Splenic biopsies can be divided into ultrasound-guided, computed tomography (CT)-guided fine-needle aspiration, or core needle biopsy (CNB). However, few studies have focused exclusively on complications associated with CT-guided CNB of the spleen. Therefore, we assessed bleeding, the most common complication of CT-guided CNB of the spleen, and evaluated factors associated with the bleeding. Using the biopsy database maintained at the institution, all patients who underwent CT-guided CNB of the spleen between May 2012 and September 2022 were identified retrospectively. The 18 identified patients were divided into post-biopsy bleeding and non-bleeding groups for analysis. In total, 17 patients (94.4%) could be diagnosed accurately with CT-guided CNB. Bleeding complications occurred in 7 cases of CT-guided CNB; of these, 2 patients with Common Terminology Criteria for Adverse Events grade 4 disease required transcatheter arterial embolization. The bleeding group was characterized by diffuse spleen tumors in all cases, with significantly more diffuse spleen tumors than the non-bleeding group. CT-guided CNB is a useful option for neoplastic lesions of the spleen that are difficult to diagnose using imaging alone. However, consideration should be given to post-biopsy bleeding in patients with diffuse splenic tumors.
- 17 November 2023
- Published by Wolters Kluwer Health in Medicine
- Vol. 102 (46) , e34951
Open AccessExploration of predictors associated with bleeding in computed tomography-guided core needle splenic biopsy: A retrospective study
Splenic diseases may be caused by infections and can be either malignant, such as lymphoma and lung cancer, or benign, such as hemangioma. In some cases, diagnostic uncertainty of imaging persists, and image-guided splenic needle biopsy is a useful diagnostic tool to avoid the disadvantages of incorrect diagnosis, including performing unnecessary splenectomy or not giving the necessary treatment. Splenic biopsies can be divided into ultrasound-guided, computed tomography (CT)-guided fine-needle aspiration, or core needle biopsy (CNB). However, few studies have focused exclusively on complications associated with CT-guided CNB of the spleen. Therefore, we assessed bleeding, the most common complication of CT-guided CNB of the spleen, and evaluated factors associated with the bleeding. Using the biopsy database maintained at the institution, all patients who underwent CT-guided CNB of the spleen between May 2012 and September 2022 were identified retrospectively. The 18 identified patients were divided into post-biopsy bleeding and non-bleeding groups for analysis. In total, 17 patients (94.4%) could be diagnosed accurately with CT-guided CNB. Bleeding complications occurred in 7 cases of CT-guided CNB; of these, 2 patients with Common Terminology Criteria for Adverse Events grade 4 disease required transcatheter arterial embolization. The bleeding group was characterized by diffuse spleen tumors in all cases, with significantly more diffuse spleen tumors than the non-bleeding group. CT-guided CNB is a useful option for neoplastic lesions of the spleen that are difficult to diagnose using imaging alone. However, consideration should be given to post-biopsy bleeding in patients with diffuse splenic tumors.
- 4 November 2023
- Published by Springer Nature in Clinical Journal of Gastroenterology
- Vol. 17 (1) , 69-74
Systemic AL amyloidosis with multiple submucosal hematomas of the colon: a case report and literature review
Amyloid light-chain (AL) amyloidosis rarely causes colorectal submucosal hematoma. A 76-year-old man presented with a complaint of bloody stool. An initial colonoscopy revealed ulcerative lesions in the descending colon, leading to a diagnosis of ischemic colitis. One month later, he presented with cardiac failure, suspected cardiac amyloidosis, and underwent a second colonoscopy. Although it revealed multiple ulcerative lesions from the ascending to transverse colon, biopsy samples did not confirm amyloid deposition. He underwent a third colonoscopy 3 weeks later due to recurrent bloody stool. It showed multiple submucosal hematomas from the ascending to descending colon concomitant with ulcerative lesions in the descending colon and multiple elevated lesions in the sigmoid colon. Biopsy samples confirmed amyloid deposition. Using a systemic search, multiple myeloma with AL amyloidosis was diagnosed. Colorectal submucosal or intramural hematomas are conditions usually encountered in trauma, antithrombotic use, or coagulation disorders. Based on our review of the literatures, we identified several differences between colorectal intramural hematoma caused by amyloidosis and those caused by other etiologies. We believe that amyloidosis should be considered when relatively small and multiple colorectal hematomas, not restricted to the sigmoid colon, and with concomitant findings of erosions and ulcers, are observed.
- 4 November 2023
- Published by Springer Nature in Clinical Journal of Gastroenterology
- Vol. 17 (1) , 69-74
Systemic AL amyloidosis with multiple submucosal hematomas of the colon: a case report and literature review
Amyloid light-chain (AL) amyloidosis rarely causes colorectal submucosal hematoma. A 76-year-old man presented with a complaint of bloody stool. An initial colonoscopy revealed ulcerative lesions in the descending colon, leading to a diagnosis of ischemic colitis. One month later, he presented with cardiac failure, suspected cardiac amyloidosis, and underwent a second colonoscopy. Although it revealed multiple ulcerative lesions from the ascending to transverse colon, biopsy samples did not confirm amyloid deposition. He underwent a third colonoscopy 3 weeks later due to recurrent bloody stool. It showed multiple submucosal hematomas from the ascending to descending colon concomitant with ulcerative lesions in the descending colon and multiple elevated lesions in the sigmoid colon. Biopsy samples confirmed amyloid deposition. Using a systemic search, multiple myeloma with AL amyloidosis was diagnosed. Colorectal submucosal or intramural hematomas are conditions usually encountered in trauma, antithrombotic use, or coagulation disorders. Based on our review of the literatures, we identified several differences between colorectal intramural hematoma caused by amyloidosis and those caused by other etiologies. We believe that amyloidosis should be considered when relatively small and multiple colorectal hematomas, not restricted to the sigmoid colon, and with concomitant findings of erosions and ulcers, are observed.
- Open Access
- 22 June 2023
- Published by Romanian Society of Gastroenterology and Hepatology in Journal of Gastrointestinal and Liver Diseases
- Vol. 32 (2) , 216-221
Endoscopic Papillary Balloon Dilation Can Be Safely Performed in Patients on Dual Antiplatelet Therapy: A Pilot Study
Background and Aims: Endoscopic papillary balloon dilation (EPBD), a low-risk procedure for bleeding, hasbeen suggested as an alternative to endoscopic sphincterotomy for papillary dilatation in patients undergoingendoscopic stone removal who are at a higher risk of bleeding. Several guidelines recommend that combinationof two antiplatelet agents should be reduced to single antiplatelet therapy when endoscopic sphincterotomyis performed. However, there is no evidence that EPBD affects the risk of bleeding in patients receiving acombination of two antiplatelet agents; thus, we aimed to explore this problem. Methods: We included 31 patients who underwent EPBD for common bile duct stones at our hospital fromMay 2014 to August 2022 and received either a combination of two antiplatelet agents or single antiplatelettherapy prior to the procedure. The group receiving a combination of two antiplatelet agents included patientswho underwent EPBT without antiplatelet therapy withdrawal or with a shorter withdrawal period than thoserecommended by the guidelines. Results: In the group that received a combination of two antiplatelet agents, one of the two antiplateletagents used was thienopyridine. No bleeding was observed after EPBD in this study. We did not findany significant between-group differences in hemoglobin levels and rate of post-endoscopic retrogradecholangiopancreatography pancreatitis. Conclusions: In patients treated with a combination of two antiplatelet agents, EPBD could be safely performedwithout bleeding. Therefore, future prospective studies are warranted.
- 22 June 2023
- Published by Romanian Society of Gastroenterology and Hepatology in Journal of Gastrointestinal and Liver Diseases
- Vol. 32 (2) , 216-221
Open AccessEndoscopic Papillary Balloon Dilation Can Be Safely Performed in Patients on Dual Antiplatelet Therapy: A Pilot Study
Background and Aims: Endoscopic papillary balloon dilation (EPBD), a low-risk procedure for bleeding, hasbeen suggested as an alternative to endoscopic sphincterotomy for papillary dilatation in patients undergoingendoscopic stone removal who are at a higher risk of bleeding. Several guidelines recommend that combinationof two antiplatelet agents should be reduced to single antiplatelet therapy when endoscopic sphincterotomyis performed. However, there is no evidence that EPBD affects the risk of bleeding in patients receiving acombination of two antiplatelet agents; thus, we aimed to explore this problem. Methods: We included 31 patients who underwent EPBD for common bile duct stones at our hospital fromMay 2014 to August 2022 and received either a combination of two antiplatelet agents or single antiplatelettherapy prior to the procedure. The group receiving a combination of two antiplatelet agents included patientswho underwent EPBT without antiplatelet therapy withdrawal or with a shorter withdrawal period than thoserecommended by the guidelines. Results: In the group that received a combination of two antiplatelet agents, one of the two antiplateletagents used was thienopyridine. No bleeding was observed after EPBD in this study. We did not findany significant between-group differences in hemoglobin levels and rate of post-endoscopic retrogradecholangiopancreatography pancreatitis. Conclusions: In patients treated with a combination of two antiplatelet agents, EPBD could be safely performedwithout bleeding. Therefore, future prospective studies are warranted.
- 16 January 2023
- Published by Springer Nature in Clinical Journal of Gastroenterology
- Vol. 16 (2) , 146-151
Gastric adenocarcinoma of fundic gland type with autoimmune gastritis
An 87-year-old man with dysphagia presented to our hospital. He was diagnosed with autoimmune gastritis (AIG) with severe atrophy and hypergastrinemia. The patient was positive for parietal cell antibody (PCA) and anti-intrinsic factor antibody (IFA), without evidence of H. pylori infection. A flat elevated tumor was detected in the middle corpus, and therapeutic endoscopic submucosal dissection was performed. Histopathological examination revealed atypical cells mimicking the fundic glands, which were positive for pepsinogen-I and partially positive for MUC6 and H + /K + -ATPase, proliferating to the deep layer. The final diagnosis was gastric adenocarcinoma of the fundic gland type (GAFG). AIG is expected to be difficult to develop GAFG because the basal gastric glands are highly atrophic due to the production of PCA. However, some chief cells may remain and could have the potential to develop into malignancy during AIG progression. Therefore, careful observation is required in patients with AIG when considering the occurrence of GAFG.
- 16 January 2023
- Published by Springer Nature in Clinical Journal of Gastroenterology
- Vol. 16 (2) , 146-151
Gastric adenocarcinoma of fundic gland type with autoimmune gastritis
An 87-year-old man with dysphagia presented to our hospital. He was diagnosed with autoimmune gastritis (AIG) with severe atrophy and hypergastrinemia. The patient was positive for parietal cell antibody (PCA) and anti-intrinsic factor antibody (IFA), without evidence of H. pylori infection. A flat elevated tumor was detected in the middle corpus, and therapeutic endoscopic submucosal dissection was performed. Histopathological examination revealed atypical cells mimicking the fundic glands, which were positive for pepsinogen-I and partially positive for MUC6 and H + /K + -ATPase, proliferating to the deep layer. The final diagnosis was gastric adenocarcinoma of the fundic gland type (GAFG). AIG is expected to be difficult to develop GAFG because the basal gastric glands are highly atrophic due to the production of PCA. However, some chief cells may remain and could have the potential to develop into malignancy during AIG progression. Therefore, careful observation is required in patients with AIG when considering the occurrence of GAFG.
- Open Access
- 10 May 2022
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 11 (10) , 2697
Antibiotic Administration within Two Days after Successful Endoscopic Retrograde Cholangiopancreatography Is Sufficient for Mild and Moderate Acute Cholangitis
To prevent the increase of resistant bacteria, it is important to minimize the use of antimicrobial agents. Studies have found that administration for ≤3 days after successful endoscopic retrograde cholangiopancreatography (ERCP) is appropriate. Therefore, the present study aimed to verify if administration of antimicrobial agents can be further shortened to ≤2 days after ERCP. We divided 390 patients with mild and moderate cholangitis who underwent technically successful ERCP from January 2018 to June 2020 and had positive blood or bile cultures into two groups: antibiotic therapy within two days of ERCP (short-course therapy, SCT; n = 59, 15.1%), and for >3 days (long-course therapy, LCT; n = 331, 84.9%). The increased severity after admission and other outcomes were compared between the two groups, and the risk factors for increased severity were verified. There were no between-group differences in patient characteristics. Total length of hospital stay was shorter in SCT than in LCT, and other outcomes in SCT were not significantly different from those in LCT. Being 80 or older was a risk factor for increased severity; however, SCT was not associated with increased severity. Antimicrobial therapy for ≤2 days after successful ERCP is adequate in patients with mild and moderate acute cholangitis.
- 10 May 2022
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 11 (10) , 2697
Open AccessAntibiotic Administration within Two Days after Successful Endoscopic Retrograde Cholangiopancreatography Is Sufficient for Mild and Moderate Acute Cholangitis
To prevent the increase of resistant bacteria, it is important to minimize the use of antimicrobial agents. Studies have found that administration for ≤3 days after successful endoscopic retrograde cholangiopancreatography (ERCP) is appropriate. Therefore, the present study aimed to verify if administration of antimicrobial agents can be further shortened to ≤2 days after ERCP. We divided 390 patients with mild and moderate cholangitis who underwent technically successful ERCP from January 2018 to June 2020 and had positive blood or bile cultures into two groups: antibiotic therapy within two days of ERCP (short-course therapy, SCT; n = 59, 15.1%), and for >3 days (long-course therapy, LCT; n = 331, 84.9%). The increased severity after admission and other outcomes were compared between the two groups, and the risk factors for increased severity were verified. There were no between-group differences in patient characteristics. Total length of hospital stay was shorter in SCT than in LCT, and other outcomes in SCT were not significantly different from those in LCT. Being 80 or older was a risk factor for increased severity; however, SCT was not associated with increased severity. Antimicrobial therapy for ≤2 days after successful ERCP is adequate in patients with mild and moderate acute cholangitis.